Related references
Note: Only part of the references are listed.The mode of action of anticancer gold-based drugs: a structural perspective
Luigi Messori et al.
CHEMICAL COMMUNICATIONS (2013)
Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study
Aviva Levina et al.
CHEMISTRY-A EUROPEAN JOURNAL (2013)
Interaction of Anticancer Ruthenium Compounds with Proteins: High-Resolution X-ray Structures and Raman Microscopy Studies of the Adduct between Hen Egg White Lysozyme and AziRu
Alessandro Vergara et al.
INORGANIC CHEMISTRY (2013)
Peculiar Features in the Crystal Structure of the Adduct Formed between cis-PtI2(NH3)2 and Hen Egg White Lysozyme
Luigi Messori et al.
INORGANIC CHEMISTRY (2013)
Investigating the Ruthenium Metalation of Proteins: X-ray Structure and Raman Microspectroscopy of the Complex between RNase A and AziRu
Alessandro Vergara et al.
INORGANIC CHEMISTRY (2013)
Ruthenium-based complex nanocarriers for cancer therapy
Gaetano Mangiapia et al.
BIOMATERIALS (2012)
Next-Generation Anticancer Metallodrugs
Seiji Komeda et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A Targeting Non-Covalent Interactions with Albumin
Michael I. Webb et al.
INORGANIC CHEMISTRY (2012)
Increasing the X-ray Diffraction Power of Protein Crystals by Dehydration: The Case of Bovine Serum Albumin and a Survey of Literature Data
Irene Russo Krauss et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates
A. Bergamo et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Exploring the mechanisms of metal-based pharmacological agents via an integrated approach
Angela Casini
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
New insights into the chemistry of fac-[Ru(CO)3]2+ fragments in biologically relevant conditions: The CO releasing activity of [Ru(CO)3Cl2(1,3-thiazole)], and the X-ray crystal structure of its adduct with lysozyme
M. F. A. Santos et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Direct cryocooling of naked crystals: are cryoprotection agents always necessary?
Erika Pellegrini et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2011)
REFMAC5 for the refinement of macromolecular crystal structures
Garib N. Murshudov et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Towards Improved Therapeutic CORMs: Understanding the Reactivity of CORM-3 with Proteins
T. Santos-Silva et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Metal-based anti-diabetic drugs: advances and challenges
Aviva Levina et al.
DALTON TRANSACTIONS (2011)
In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A
Zdenek Travnicek et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2011)
Organometallic ruthenium-based antitumor compounds with novel modes of action
Wee Han Ang et al.
JOURNAL OF ORGANOMETALLIC CHEMISTRY (2011)
CORM-3 Reactivity toward Proteins: The Crystal Structure of a Ru(II) Dicarbonyl-Lysozyme Complex
Teresa Santos-Silva et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin
Michael Groessl et al.
METALLOMICS (2011)
The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins
Angela Casini et al.
CHEMMEDCHEM (2010)
Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action
Angela Casini et al.
METALLOMICS (2009)
Recent developments in ruthenium anticancer drugs
Aviva Levina et al.
METALLOMICS (2009)
Ruthenium anticancer drugs and proteins:: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c
Angela Casini et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2007)
Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole):: Aquation, redox properties, protein binding, and antiproliferative activity
Michael Groessl et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes
Angela Casini et al.
CHEMMEDCHEM (2007)
Metal based drugs: from serendipity to design
Simon Paul Fricker
DALTON TRANSACTIONS (2007)
From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2006)
Metal-based antitumour drugs in the post genomic era
PJ Dyson et al.
DALTON TRANSACTIONS (2006)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the Ruthenium(III) complexes [TzH][trans-RUCl4(Tz)2] and [TzH][trans-RUCl4(DMSO)(Tz)]•(DMSO), the thiazole analogues of antitumor ICR and NAMI-A
P Mura et al.
INORGANIC CHEMISTRY (2004)
Half-sandwich arene ruthenium(II)-enzyme complex
IW McNae et al.
CHEMICAL COMMUNICATIONS (2004)
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A
M Bouma et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2002)
A spectroscopic study of the reaction of NAMI, a novel ruthenium(III) anti-neoplastic complex, with bovine serum albumin
L Messori et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Share Paper
